Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antigen Ki-67 analýza MeSH
- antigeny CD34 analýza MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- lymfom z plášťových buněk patologie terapie MeSH
- mikrocévy patologie fyziologie MeSH
- nádorové biomarkery analýza MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- proliferace buněk MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigen Ki-67 MeSH
- antigeny CD34 MeSH
- nádorové biomarkery MeSH
The clinical course and therapy of mantle cell lymphoma (MCL) are heterogeneous and often unsatisfactory. Prognostic factors are needed to stratify the patients. Microvessel density (MVD) has prognostic significance in some malignancies. There is little information about the vasculature of MCL, although some antiangiogenic drugs are in use. We studied MVD using systematic uniform random sampling and unbiased counting frames in immunohistochemical reactions with anti-CD34 antibody in pre-therapeutic extramedullary MCL samples of 177 patients. We analyzed the relationship of MVD to overall survival (OS) and progression-free survival (PFS), as well as to proliferative activity (Ki-67), mantle cell lymphoma prognostic index (MIPI), morphological variant, pattern of growth, and localization. MVD varied widely: range 54.6-503.6 vessels/mm(2), median 158.2 vessels/mm(2). Higher MVD was associated with bone marrow infiltration at the time of diagnosis (P = 0.001). High MVD was associated with significantly worse OS (P = 0.04) only in patients treated with non-intensive (conventional) therapy. MVD correlated positively with MIPI scores but not with the proliferation, morphological variant, growth pattern, or localization. Univariate analysis identified a prognostic influence of morphological variant, MIPI, and proliferative activity on OS and PFS and a prognostic influence of bone marrow infiltration at the time of diagnosis on PFS. Multivariate analysis showed prognostic influence of MIPI and proliferative activity on OS and PFS only. In conclusion, this is the first clinicopathological study of MVD of MCL with long-term follow-up showing negative prognostic trends of high MVD in MCL and positive correlation of MVD and MIPI.
Zobrazit více v PubMed
N Engl J Med. 2012 Aug 9;367(6):520-31 PubMed
Blood. 2008 Jan 15;111(2):558-65 PubMed
Haematologica. 2012 Mar;97(3):416-22 PubMed
Eur J Cancer. 2010 Sep;46(13):2506-12 PubMed
J Hematop. 2009 Jul;2(2):103-11 PubMed
Br J Haematol. 2010 Jul;150(2):200-8 PubMed
Cancer Res. 2004 May 1;64(9):2941-55 PubMed
Bone Marrow Transplant. 2004 Aug;34(3):235-9 PubMed
Ann Oncol. 2010 Jan;21(1):133-9 PubMed
Lab Invest. 2008 Jan;88(1):38-47 PubMed
APMIS. 2001 Jan;109(1):66-72 PubMed
J Clin Pathol. 2004 Aug;57(8):856-60 PubMed
Microsc Res Tech. 2008 Oct;71(10):760-72 PubMed
Blood. 2010 Feb 25;115(8):1530-3 PubMed
Blood. 2008 Oct 1;112(7):2687-93 PubMed
Blood. 2008 Sep 15;112(6):2583; author reply 2583-4 PubMed
Haematologica. 2011 Jul;96(7):996-1001 PubMed
Leuk Lymphoma. 2014 Apr;55(4):802-10 PubMed
Res Vet Sci. 2008 Aug;85(1):56-61 PubMed
Ann Oncol. 2009 Mar;20(3):413-24 PubMed
Eur J Haematol. 2002 Jul;69(1):11-20 PubMed
Leuk Lymphoma. 1996 Mar;21(1-2):115-25 PubMed
Leukemia. 2004 Jul;18(7):1200-6 PubMed
Blood. 2008 Feb 15;111(4):2385-7 PubMed
Clin Cancer Res. 2005 Jan 1;11(1):154-61 PubMed
Cancer. 2010 Jun 1;116(11):2655-64 PubMed
Cancer Res. 2010 Feb 15;70(4):1408-18 PubMed
J Clin Oncol. 2014 May 1;32(13):1338-46 PubMed
Br J Haematol. 2005 Oct;131(1):29-38 PubMed
Prostate Cancer Prostatic Dis. 2002;5(2):123-7 PubMed
J Clin Pathol. 2007 May;60(5):476-82 PubMed
Cancer Sci. 2010 Mar;101(3):806-14 PubMed
Blood. 2006 Apr 15;107(8):3407 PubMed
Haematologica. 2010 Sep;95(9):1503-9 PubMed
Blood. 1997 Feb 15;89(4):1421-9 PubMed
J Hematol Oncol. 2010 Sep 09;3:30 PubMed
Histopathology. 2013 Oct;63(4):499-508 PubMed
Mod Pathol. 1996 Apr;9(4):361-6 PubMed
Blood. 1997 Mar 15;89(6):2067-78 PubMed
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas